Detalhe da pesquisa
1.
Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up.
Ann Rheum Dis;
74(10): 1825-9, 2015 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24812290
2.
Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects.
Ann Rheum Dis;
74(2): 361-8, 2015 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24265411
3.
Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients.
Ann Rheum Dis;
71(1): 88-91, 2012 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21914626
4.
Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.
Arthritis Rheum;
63(4): 877-83, 2011 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21452312
5.
Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study.
RMD Open;
8(1)2022 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35383121
6.
Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs.
Ann Rheum Dis;
74(2): 474-5, 2015 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25433018
7.
Adherence to etanercept therapy in rheumatoid arthritis patients during 3 years of follow-up.
PLoS One;
13(10): e0205125, 2018.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30300358